Prestige BioPharma Limited

A950210

KR8702070002

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
8,000 ^KRW	-0.12%		-0.37%	-15.61%

2023	Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer	CI
2023	Prestige BioPharma Limited Develops First-In-Class PAUF-detecting Diagnostic Kit	CI

Prestige Biologics Co., Ltd. announced that it expects to receive KRW 6.893915 billion in funding from Prestige BioPharma Limited

August 25, 2022

Prestige Biologics Co., Ltd. announced a private placement of 13,787,830 shares at a share price of KRW 500 per share for the gross proceeds of KRW 6,893,915,000? on August 26, 2022. The expected payment date is September 5, 2022.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	PRESTIGE BIOPHARMA LIMITED	8,000 KRW	-0.12%	-0.37%	69.86M
	PRESTIGE BIOLOGICS CO., LTD.	4,160 KRW	-0.72%	+1.22%	186M

Latest news about Prestige BioPharma Limited

Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer	23-03-21	CI
Prestige BioPharma Limited Develops First-In-Class PAUF-detecting Diagnostic Kit	23-03-09	CI
Prestige Biopharma Submits Pre-BLA Type 4 Meeting Request to FDA for Herceptin Biosimilar	22-10-13	CI
Prestige Biologics Co., Ltd. announced that it has received KRW 6.893915 billion in funding from Prestige BioPharma Limited	22-09-04	CI
Prestige Biologics Co., Ltd. announced that it expects to receive KRW 6.893915 billion in funding from Prestige BioPharma Limited	22-08-25	CI
Prestige Biopharma and Intas Pharmaceuticals Announce Partnership to Commercialize Bevacizumab Biosimilar in the Us, Europe, Canada, Mena, Brazil, Mexico, South Africa, Cis and the Sea Countries	22-07-26	CI
US FDA Approves Prestige Biopharma’s IND for Phase 1/2a Trial of First-in-Class Pancreatic Cancer Treatment, PBP1510	22-06-27	CI
Prestige Biopharma Enters MOU with Vaxine for Supply of COVID-19 Vaccine and Co-development of COVID-19/Influenza Combo Vaccine	22-03-29	CI
The Result of the Phase 3 Study for Prestige BioPharma’s Herceptin Biosimilar, HD201(Tuznue®), Published in JAMA Oncology	22-03-11	CI
Prestige BioPharma Limited Announces Preclinical Data of Pancreatic Cancer Treatment, PBP1510, Present in ESMO TAT 2022	22-03-08	CI
Prestige BioPharma Limited Commences Construction of Innovative Discovery Center in Busan, Korea	21-12-19	CI
Prestige BioPharma and Dr. Reddy’s Announce Partnership to Commercialize Trastuzumab Biosimilar in Select Countries in Latin America and Southeast Asia	21-12-08	CI
Prestige BioPharma Limited(KOSE:A950210) added to S&P Global BMI Index	21-09-20	CI

Chart Prestige BioPharma Limited

Duration

Period

More charts

Company Profile

Prestige Biopharma Ltd is a Singapore-based biopharmaceutical company. The Company is focused on the development of biosimilars and antibody drugs as well as vaccines for infectious diseases. Its biosimilar portfolio consists of over 12 pipelines, including HD201 (trastuzumab) in Phase III, HD204 (bevacizumab) in Phase III, and PBP1502 (adalimumab) in Phase I. Its antibody therapeutic portfolio includes PBP1510, PBP1710, IDC001, IDC005, IDC007, IDC008 and others. PBP1510 specifically binds pancreatic adenocarcinoma upregulated factor (PAUF), a protein that drives cancer cells to spread through blood flow and to escape immune recognition and exerts anti-metastasis and immune modulation effects. PBP1710 specifically binds to collagen triple helix repeat containing 1 (CTHRC1), a protein that facilitates cancer cells and exerts anti-metastasis and anti-tumor growth effects. IDC001 is designed to treat cancers that express high level of PAUF and CTHRC1.

Sector

Pharmaceuticals

Calendar

2024-09-16 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
PRESTIGE BIOPHARMA LIMITED	-15.61%	69.86M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals

Prestige BioPharma Limited

Equities

A950210

KR8702070002

Pharmaceuticals

Prestige Biologics Co., Ltd. announced that it expects to receive KRW 6.893915 billion in funding from Prestige BioPharma Limited

Stocks mentioned in the article

Latest news about Prestige BioPharma Limited

Chart Prestige BioPharma Limited

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Biopharmaceuticals